Flagship Pioneering and ProFound Therapeutics Announce Agreement to Identify Novel First-in-Class Therapeutics for the Treatment of Obesity Under Strategic Partnership With Pfizer
Foghorn Therapeutics to Participate in Upcoming Investor Conferences in June
Foghorn Therapeutics Raises ~$110 Million Through Direct Offering
Foghorn Therapeutics raised approximately $110 million through registered direct offering to advance pipeline construction
Foghorn Therapeutics raised approximately $110 million through registered direct offering to advance pipeline construction
Foghorn Therapeutics Inc.: Deferring Cash Flow to 2027
Foghorn Therapeutics Inc.: Deferring Cash Flow to 2027
Express News | Foghorn Therapeutics Inc.: Extends Cash Runway Into 2027
Express News | Foghorn Therapeutics Raises Approximately $110 Million Through Registered Direct Offering to Advance Pipeline
Foghorn Prices $110M Mixed-shelf Registered Direct Offering
Foghorn Announces Pricing of Registered Direct Offering of Common Stock and Pre-Funded Warrants
Investors Don't See Light At End Of Foghorn Therapeutics Inc.'s (NASDAQ:FHTX) Tunnel And Push Stock Down 25%
Foghorn Therapeutics First Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Foghorn Therapeutics (FHTX.US): The 2024 Q1 financial report achieved revenue of US$5.05 million, with a previous value of US$5.39 million and an expected value of US$6.91 million; earnings per share were -0.59 dollars, previous value was -0.73 dollars, a
Foghorn Therapeutics (FHTX.US): The 2024 Q1 financial report achieved revenue of US$5.05 million, with a previous value of US$5.39 million and an expected value of US$6.91 million; earnings per share were -0.59 dollars, previous value was -0.73 dollars, and expected value was -0.63 dollars.
Foghorn Therapeutics Q1 2024 Earnings: Misses Analyst Revenue Projections Amidst Strategic ...
Foghorn Therapeutics | 10-Q: Quarterly report
Press Release: Foghorn Therapeutics Provides First Quarter 2024 Financial and Corporate Update
Foghorn Therapeutics Cash, Cash Equivalents, and Marketable Securities of $206.7 M, as of March 31 >FHTX
Foghorn Therapeutics 1Q Loss/Shr 59c >FHTX
Foghorn Therapeutics 1Q Loss $25M >FHTX
Analysts' Top Healthcare Picks: Stryker (SYK), Foghorn Therapeutics (FHTX)
Insiders Sold Foghorn Therapeutics At US$6.56, Meanwhile Stock Sits Near US$5.53